The FDA still doesn’t recognize “aging” as a disease you can get a prescription for. That single fact shapes everything in this article: every drug below is technically being tested for a specific condition (an eye disease, obesity, cognitive decline), even though the researchers behind it are explicitly chasing something bigger. A 2025 systematic review from George Washington University put it plainly: the human evidence for most of these approaches “remains unestablished.” We agree with that framing, and we’re going to hold onto it through all five entries.
So this isn’t a hype list. It’s five drugs currently in human trials, real ones, with real participant counts, that target the biological processes researchers believe actually drive aging. We’ll tell you the mechanism, the study size, whether it’s academic or company-funded, and how far it realistically is from your medicine cabinet. 🧬
A gene therapy trying to rewind cells in the human eye
In June 2026, a Boston company called Life Biosciences dosed the first human participant with ER-100, a gene therapy built around partial epigenetic reprogramming. The mechanism, in plain terms: instead of turning old cells all the way back into stem cells (which risks cancer), the therapy nudges specific chemical tags on DNA back toward a younger pattern, aiming to restore function without erasing the cell’s identity. It’s delivered directly into one eye and activated by an oral antibiotic over eight weeks. 🔬
This is a Phase 1 trial, meaning the goal right now is safety, not proof it works. Up to 18 people will be enrolled, split between glaucoma and a stroke-like optic nerve condition called NAION. Worth flagging plainly: co-founder David Sinclair, the Harvard geneticist whose lab pioneered this reprogramming theory, is also the company’s public face, which is a real conflict of interest worth keeping in mind whenever a founder is also the loudest advocate for the science.
Mechanism: partial epigenetic reprogramming (Yamanaka-factor-adjacent, but incomplete on purpose)
Study size: up to 18 participants, Phase 1
Funded by: Life Biosciences (the drug’s own maker)
Realistic timeline: years away from anything beyond the eye, if it works at all
If it’s safe and the eye responds, the company has said it wants to move toward the liver and eventually other organs. That’s a big if, stacked on another big if.
Rapamycin moves from off-label buzz to actual trial data
Rapamycin is the drug longevity forums have been buzzing about for a decade, an old immunosuppressant that reliably extends lifespan in mice, worms, and flies by blocking a growth-signaling pathway called mTOR. The gap has always been human proof, and 2025 finally delivered some. The PEARL trial, a 48-week randomized, placebo-controlled study of 114 adults aged 50 to 85, tested weekly doses of 5 mg or 10 mg against placebo. Published in the journal Aging in 2025, it found the drug safe and well tolerated, with the standout signal being a roughly 6 percent gain in lean tissue mass among women on the higher dose. It did not measure lifespan, and it wasn’t built to. Be honest with yourself about what that means: safety and a lean-mass signal are real findings, but they’re a long way from “slows aging.”
We’d be doing you a disservice not to flag the funding here. PEARL was run by AgelessRx, a telehealth company that prescribes rapamycin, and crowdfunded in part through the advocacy group lifespan.io. That doesn’t make the data wrong, but it’s a company with a direct commercial interest in a positive result, which is exactly the kind of thing we think you deserve to know before reading too much into it.
Meanwhile, a genuinely independent trial is quietly running right now: Columbia University is testing whether low-dose rapamycin can delay ovarian aging in perimenopausal women, a randomized, triple-masked Phase 2 study that’s currently active. It’s a much narrower question than “does this drug slow human aging,” but it’s the kind of tightly scoped, academically run trial this field needs more of.
Animal evidence: strong and repeatedly replicated across species
Human evidence: one 48-week RCT, safety-focused, funded by a company that sells the drug
Ongoing independent work: a Columbia University trial on ovarian aging specifically
Bottom line: promising, unproven, and worth watching rather than acting on
A senolytic eye drug is already showing results in people
Here’s where the data gets stronger, at least for one narrow use case. Senolytics are drugs designed to clear out senescent cells, the “zombie cells” that stop dividing but refuse to die, instead pumping out inflammatory signals that damage the tissue around them. Foselutoclax (also called UBX1325), made by Unity Biotechnology, is a small molecule that blocks a survival protein these zombie cells depend on.
Two separate trials in diabetic macular edema, a leading cause of blindness, have now reported results. The Phase 2 BEHOLD study, 65 participants, found a single injection improved vision by an average of 6.2 letters on a standard eye chart at 48 weeks, a significant edge over sham treatment. The larger Phase 2b ASPIRE trial, 52 participants who’d already failed standard anti-VEGF treatment, found the drug held its own against aflibercept, the current gold-standard therapy, through 36 weeks. Both trials were published in peer-reviewed journals, including NEJM Evidence. 💊
This is company-funded research (Unity Biotechnology makes the drug), so treat the topline numbers with the same healthy skepticism you’d apply to any sponsor-run trial. But this is also, genuinely, the most mature clinical evidence on this list that a senolytic mechanism does something measurable in real human tissue. The catch: it’s a local injection into the eye, not a systemic anti-aging pill, and Unity is still working out what comes next for the broader program.
The systemic senolytic combo everyone’s biohacking, now in real pilot trials
If foselutoclax is the narrow, well-funded senolytic story, dasatinib plus quercetin (D+Q) is the messy, grassroots one. This combination, a repurposed leukemia drug paired with a plant flavonoid supplement, has become the most self-administered senolytic protocol among longevity enthusiasts, largely because both ingredients are already available. The actual clinical evidence is much thinner than the enthusiasm.
A 2025 pilot study published in eBioMedicine gave older adults at risk for Alzheimer’s disease two days of D+Q every two weeks for 12 weeks. It found the treatment feasible and safe, with a small, not-quite-significant bump in cognitive scores. A separate Phase 1 trial in people already diagnosed with Alzheimer’s, published in Neurotherapeutics, found almost no significant biomarker changes and, honestly, no real suggestion the drug was doing much of anything for that population. 😐 A third pilot, currently recruiting through Washington University in St. Louis, is testing the same combination in people with schizophrenia and treatment-resistant depression, on the theory that these conditions involve accelerated biological aging.
What it targets: senescent cells throughout the body, not one organ
Human evidence so far: multiple small, mostly academic pilot studies (n=20 to 30)
What we’ve seen: safety and feasibility confirmed, meaningful efficacy not yet shown
Funding: largely NIH and university-backed, less commercial conflict than most entries here
We’ll say it plainly: the animal data on D+Q is genuinely compelling, and the human safety data is reassuring. The human efficacy data, so far, just isn’t there yet. Anyone taking this off-label right now is running ahead of the evidence, not following it.
A drug built to calm the inflammation that drives aging itself
Our last pick is the newest to enter human testing. BGE-102, made by BioAge Labs, targets a protein complex called NLRP3, a central driver of inflammaging, the low-grade, chronic inflammation that climbs steadily with age and is linked to everything from heart disease to cognitive decline. Early Phase 1 data, presented in mid-2026, showed the drug cut a key inflammatory marker called hsCRP by a median of roughly 85 percent in people with obesity and elevated baseline inflammation. That’s a striking number for an early trial, though hsCRP is a biomarker, not a disease outcome, and biomarker drops don’t always translate into people actually feeling or living better. 🧠
BioAge dosed the first participant in a larger Phase 2 trial called QUELL-CV this past June, testing three doses against placebo in roughly 160 adults, with results expected later this year. It’s worth mentioning that this isn’t the company’s first attempt at a metabolic-aging drug: their earlier candidate, azelaprag, was discontinued in early 2025 after some participants showed liver enzyme elevations, a reminder that even well-funded, scientifically sound programs fail on safety grounds regularly in this field. That kind of course correction is normal drug development, not a scandal, but it’s exactly the sort of detail that gets left out of the more breathless coverage of this space. If you’re the type of reader who wants to track which companies are running which trials as these programs shift, LongevityHub Pro is where we keep that picture updated as it changes.
Mechanism: NLRP3 inflammation pathway inhibition
Early signal: ~85% median reduction in hsCRP, Phase 1, company-reported
Current trial: QUELL-CV, Phase 2, ~160 participants, dosing since June 2026
Funded by: BioAge Labs, the drug’s own developer
None of these five drugs are close to a prescription you can ask your doctor for tomorrow. We’ve covered rapamycin’s off-label rise before, and if you want the wider menu of drugs researchers are chasing for lifespan extension, we broke down six other medications under investigation in an earlier piece, alongside a look at the clinics already offering some of these therapies abroad if you’re curious how far ahead of the FDA some people are already moving.
Which of these five would you actually want to see published results on first? For our money, it’s whichever one finally forces the FDA to sit down and define what “aging” even means as a treatable condition. Everything else is downstream of that fight.